- Home
- CATX vs TNYA Comparison
CATX vs TNYA Comparison
Compare CATX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | TNYA |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.1M | 234.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CATX | TNYA |
|---|---|---|
| Price | $2.74 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $11.56 | $7.80 |
| AVG Volume (30 Days) | 1.4M | ★ 7.7M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,075,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $0.36 |
| 52 Week High | $5.39 | $2.35 |
Technical Indicators
Market Signals| Indicator | CATX | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 31.25 |
| Support Level | $2.67 | $0.66 |
| Resistance Level | $2.88 | $0.76 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 64.44 | 4.64 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.